Biyoaktif organorutenyum komplekslerinin sentezi

Ruthenium complexes are attracting current interest as one variety of promising metal‐base anticancer drugs because of their specific biological functions. This mainly because of their ability to form compounds with interesting electronic structures, uncommon co-ordination number, unusual stereochemistry, along with their broad spectrum of biologic areas, such as antiviral, antifungal, antibacterial, antioxidant activities, anticarcinogenic, antitumor, DNA binding abilities and insulin mimetic effects. Herein antiproliferative activity, characterization and synthesis of "half-sandwich" organo-ruthenium(II) compounds [(η6-p-cym)Ru(N,S-TSC)Cl]Cl (I, II and III), which TSC= 5-nitro-2-carboxyaldehyde-thiophen-N-methyl-thiosemicarbazone, (TSC1); 2-acetyl-5-bromo-thiophen-N-methyl-thiosemicarbazone, (TSC2) and 2-acetyl-5-bromo-thiophen-N,N-dimethyl-thiosemicarbazone, (TSC3), were reported, respectively. The purified complexes were analyzed using many spectroscopic techniques like 1H NMR spectroscopy, FT-IR, elemental analysis, single-crystal XRD, MALDI-TOF mass spectrometry and UV-Vis spectroscopy. These studies shows that TSCs demonstrate abilitiy to bind bidentate. This ligands have the property of binding via azomethine nitrogen atoms and thiocarbonyl sulphur metal atoms with all complexes (I, II, III). Crystalline forms of TSC1 and TSC2 were revealed by X-ray spectroscopy. These compounds crystallize with the P-1 space group in the triclinic crystal system. Biological potential studies were performed on TSC ligands and their ruthenium compounds (TSC1, TSC2 and TSC3) (I, II and III). Accordingly, studies were conducted on human primary ovary (A2780) and human metastatic ovary (OVCAR-3) cell lines. Our results highlight the impact that novel synthesized Ru(II) complexes can have superior biologic activity.